Shield Pilots Ironclad Specialty Future With Feraccru
Executive Summary
Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach.
Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach. Co-Founder and CEO Carl Sterritt reveals to Mike Ward his ambitions to build a west European and US-focused specialty pharma while seeking in-country specialists to partner other markets.
Brought to you by the editors of Start-Up.